Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 27, 2024 08:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in...
December 13, 2024 16:30 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Streamlines Operations

ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
December 04, 2024 08:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of...
December 03, 2024 16:30 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Executive Leadership Transition

ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
November 27, 2024 06:50 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
November 06, 2024 08:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
October 17, 2024 09:00 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

Access the CEO Connect segment here ISELIN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the...
September 16, 2024 08:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
September 13, 2024 09:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Webcast replay of fireside chat now available ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory...
September 04, 2024 08:35 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Topline results from NORSE EIGHT expected in Q4 CY2024 ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved...